Australian Doctor Australian Doctor 27th October 2017 | Page 14

SPIRIVA ® Respimat ® (tiotropium)
significantly delays time to first severe
exacerbation of asthma vs placebo,
when added to ICS/LABA, p<0.05
*
* 1,2
SPIRIVA Respimat in asthma:
®
®
Now available for symptomatic adult asthma
patients as an add-on therapy to ICS/LABA †1
ICS (≥800 μg budesonide/day or equivalent) plus LABA, in patients who
experienced ≥1 severe exacerbations in the past year.
†
ICS, inhaled corticosteroids; LABA, long-acting beta 2 agonist
PBS Information: Restricted benefit. Severe Asthma Code 11043F. Refer to PBS Schedule for full restricted benefit information.
Please review Product Information before prescribing. Full Product Information is available at
www.boehringer-ingelheim.com.au/PI. Further information is available from Boehringer Ingelheim Pty Ltd.
SPIRIVA ® RESPIMAT ® (tiotropium bromide) solution for inhalation. INDICATIONS: COPD: Long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD). Prevention of COPD exacerbations. Asthma: Add-on
maintenance bronchodilator treatment in adult patients with asthma, currently treated with the maintenance combination of inhaled corticosteroids (≥800 µg budesonide/day or equivalent) and long-acting ß 2 agonists and who experienced one or more severe exacerbations in the previous
year. CONTRAINDICATIONS: Hypersensitivity to tiotropium bromide, atropine or its derivatives, or to any of the excipients. PRECAUTIONS: Should not be used for: treatment of acute episodes of bronchospasm, relief of acute symptoms, first-line treatment for asthma. Immediate
hypersensitivity reactions, narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, urinary retention, micturition difficulties, dry mouth, inhalation-induced bronchospasm, recent myocardial infarction (<6 months), unstable or life-threatening cardiac arrhythmia within
past year, hospitalisation for heart failure within past year, moderate to severe renal impairment (CrCL ≤50 mL/min), pregnancy, lactation, children. Avoid solution or mist entering eyes. INTERACTIONS: Co-administration with anticholinergic drugs. ADVERSE EFFECTS: Common: Dry
mouth, usually mild. Others, see full PI. DOSAGE: For oral inhalation. 5 μg tiotropium given as two puffs once daily, at the same time each day. Do not exceed recommended dose. Cartridges to be used only with RESPIMAT inhaler. July 2015.
References: 1. SPIRIVA Respimat Approved Product Information, 13 September 2016. 2. Kerstjens HA, et al. N Engl J Med 2012; 367: 1198–1207. SPIRIVA ® and RESPIMAT ® are registered trademarks of Boehringer Ingelheim. Boehringer
Ingelheim Pty Ltd. ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113. AUS/SPI-161245f. BISR12631W/AD/FP. July 2017.